DEEPIKA SRINIVASAN: Open Payments
NPI 1811133762 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,298 in 57 payments from 10 companies in 2025. Trend: 2023 $523 · 2024 $1,173 · 2025 $2,298
Consulting: $1,245Food & beverage: $1,053
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $1,495 |
| PFIZER INC. | 19 | $240 |
| ABBVIE INC. | 10 | $143 |
| Lilly USA, LLC | 4 | $105 |
| Janssen Scientific Affairs, LLC | 1 | $71 |
| Aimmune Therapeutics, Inc. | 4 | $65 |
| Ardelyx, Inc. | 3 | $63 |
| Novartis Pharmaceuticals Corporation | 1 | $60 |
| Celltrion USA Inc. | 2 | $31 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
Products named: TREMFYA, VELSIPITY, OMVOH, ZENPEP, LINZESS, IBSRELA, Fabhalta, MAVYRET.
Industry payments across TX — which companies pay providers there.
